TABLE 1.
Summary of single-dose i.v., i.r., and i.v.g. challenges with R5 SHIVSF162P3N
| Route | Dose (TCID50) | No. of animals | No. (%) of infected animals | No. (%) of infected animals with: |
Source or reference | |||
|---|---|---|---|---|---|---|---|---|
| AIDS | RP phenotype | Controlled infection | CoR switch | |||||
| i.v. | 3,000 | 9 | 9 (100) | 8 (89) | 6 (66.7) | 0 | 4 (44.4) | 20, 21 |
| i.r. | 10,000 | 11 | 11 (100) | 10 (91) | 4 (36.4) | 0 | 5 (45.4) | 47; this study |
| ≤1,000 | 6 | 6 (100) | 3 (50) | 1 (16.7) | 2 (33.3) | 0 | This study | |
| i.v.g. | 10,000 | 12 | 8 (66.7) | 2 (25) | 2 (25) | 2 (25) | 2 (25) | This study |
| 1,000 | 6 | 4 (66.7) | 2 (50) | 2 (50) | 2 (50) | 1 (25) | This study | |